Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Centre Hospitalier Universitaire Grenoble Alpes operates a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The company has 1 pending office action currently active. This action is being handled by 1 distinct examiner and is situated within 1 distinct art unit. This concentration reflects a focused prosecution strategy, with all current activity directed through a single channel at the patent office.
MACH, ANDRE is the busiest examiner for this portfolio, managing 1 pending office action. As the only examiner currently reviewing the company's applications, this individual's specific interpretation of Biotechnology & Pharmaceuticals patentability is paramount. Practitioners should recognize that there is no examiner overlap or diversity, making the specific feedback from MACH, ANDRE the sole guide for the company's current prosecution efforts.
The presence of 1 pending office action in 1 distinct art unit indicates that the company's current patenting efforts are highly specialized. The outcome of this single matter will be the primary driver of the company's intellectual property status in the near term. Without other examiners or art units involved, the practitioner must focus entirely on the specific technical and procedural requirements established by the current examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WAX, ROBERT A | 1 | 25.0% | +3.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17437361 | COMPOSITION AND ASSOCIATED DELIVERY DEVICE FOR HYDROGEN THERAPY | WAX, ROBERT A | 55d |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17437361 | COMPOSITION AND ASSOCIATED DELIVERY DEVICE FOR HYDROGEN THERAPY | WAX, ROBERT A | 1615 | §103 | Final Rejection | 55d | Pending | Sep 08, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial